Many new treatments for cancer are expensive and may extend life no more than a few months. As a result, the journal Lancet Oncology commissioned a report on the costs of cancer care. The authors point out that the issue of affordability will have an impact on many millions of people worldwide. Globally, about 12 million are diagnosed with cancer each year. Neither individuals nor health care systems will be able to afford some of the most recent experimental drugs.
The report offered as one example Provenge, developed to treat men with advanced prostate cancer. A three-dose course of treatment costs $100,000 and improves survival by only several months. While making no comments about the appropriateness of this particular treatment, the report says that it is essential to have thoughtful dialog about this cost issue now, before it gets completely out of control.
[Lancet Oncology, Sept., 2011]

Join Over 53,000 Subscribers at The People's Pharmacy

Each week we send two free email newsletters with breaking health news, prescription drug information, home remedies and a preview of our award-winning radio show. Join our mailing list and get the information you need to make confident choices about your health.

  1. Molly H.
    Reply

    I checked the Lancet link before asking this: Do you have any knowledge of why the drugs are so expensive in the first place? It seems like that issue should be addressed as well.

What Do You Think?

Share your thoughts with others, but be mindful of protecting your own and others' privacy. Not all comments will be posted. Advice from web visitors is not a substitute for medical attention. Do not stop any medicine without checking with the prescriber. In posting a comment, you agree to our commenting policy and website terms and conditions.